Your trusted source for investing success

Tag: diagnostics companies

Immortagen Completes Series A Financing for Personalized Medicine

Immortagen, Inc. announced that it has successfully completed its Series A financing.  Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine.  These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment.  Immortagen’s product pipeline fills

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
What Is Genetics Investing?

URL: https://investingnews.com/daily/life-science-investing/genetics-investing/what-is-genetics-investing/